Evidence map›Paper›PMID 35544646›Full record

ArticleJCO oncology practice2022

Dónde Están? Latinx/Hispanic Representation in the Oncology Workforce: Present and Future.

Narjust Duma, Ana I Velazquez, Idalid Franco, Lauren Kiel, Laura A Levit, Caroline Schenkel, Kelsey Kirkwood, Sybil Green, Gladys Rodriguez

Registry-linked trialAbstract read
In one paragraph

Article in JCO oncology practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07787806 (A Randomized Controlled, Type 1 Hybrid Effectiveness-implementation Trial Study to Compare the Effectiveness of a Patient-Reported Outcomes), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07787806 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Randomized Controlled, Type 1 Hybrid Effectiveness-implementation Trial Study to Compare the Effectiveness of a Patient-Reported Outcomes (PRO)-Driven Culturally Grounded Supportive Care Navigation in Reducing Healthcare Disparities Among Hispanic/Latinx Patients Receiving Anticancer Therapies

TypeinterventionalSponsorUniversity of California, IrvineRan2026 to 2028Enrolled72ConditionsCancerArmsPatient-Reported Outcomes (PRO)-driven supportive care navigation
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Preguntas Sobre Cáncer (Questions About Cancer): Analysis of Spanish Inquiries to the National Cancer Institute's Cancer Information Service.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Narjust DumaDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-7814-1773
Ana I VelazquezUniversity of California, San Francisco, San Francisco, CA.ORCID 0000-0002-6153-5557
Idalid FrancoHarvard Radiation Oncology Program, Boston, MA.ORCID 0000-0002-0665-3729
Lauren KielDana-Farber Cancer Institute, Boston, MA.
Laura A LevitAmerican Society of Clinical Oncology, Alexandria, VA.ORCID 0000-0001-9136-4229
Caroline SchenkelAmerican Society of Clinical Oncology, Alexandria, VA.ORCID 0000-0002-3613-8509
Kelsey KirkwoodAmerican Society of Clinical Oncology, Alexandria, VA.ORCID 0000-0002-6439-4964
Sybil GreenAmerican Society of Clinical Oncology, Alexandria, VA.
Gladys RodriguezSTART Center for Cancer Care, San Antonio, TX.ORCID 0000-0001-9136-6304

Funding

RESOURCE CENTER FOR AGING RESEARCH IN DIVERSE POPULATIONP30AG015272 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nynikka Palmer · 1997 to 2026
$19.5M
NIA NIH HHS P30 AG015272
6 · The paper itself

Abstract

This manuscript reviews the status of Hispanic/Latinx physicians in oncology, the benefits and challenges to achieving equitable representation, and potential solutions and actions to increase diversity in the oncology workforce. Persons of Hispanic/Latinx origin comprise 18.7% of the population and 16.8% of the adult population in the United States but are only 4.7% of practicing oncologists. The reasons for the lack of representation of Hispanic/Latinx individuals in medicine are multifaceted and include discrimination and biases, exclusionary practices, financial barriers, and lack of role modeling. As a result, patients are deprived the benefits of a representative workforce, such as improved access, enhanced culturally and linguistically competent care, and minimization of health disparities. Solutions included in the manuscript include a description of efforts by ASCO to improve the representativeness of the oncology workforce through its awards programs and educational efforts, especially for Hispanic/Latinx clinicians. The manuscript also outlines individual actions that attending physicians, senior oncologists, oncology leaders, and hospital/cancer center leadership can take to improve the diversity of the oncology workforce and support our Latinx/Hispanic trainees and colleagues. Improving the representativeness of the oncology workforce will require collective action by institutions, medical societies, and individuals. Nevertheless, widespread commitment to creating an inclusive and supported workforce is necessary to ensure the quality of care for minority patients, reduce existing cancer care disparities, and advance innovation in oncology.

Indexed as

Medical OncologyPhysiciansAdultCancer Care FacilitiesHispanic or LatinoHumansUnited StatesWorkforce

Identifiers

PMID35544646
PMCPMC10166382

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.